manufacturer of tirzepatide Eli Lilly sues companies selling alternative versions its weight loss drug FDA says shortage of GLP-1

Biomol Ther (Seoul)

Obesity treatment with maximum clinical evidence Tirzepatide FDA-approved as Zepbound

Recalls & Warnings February 26, 2020 Company Failed to Report Adverse Events Associated With Its Nutrition Shakes On February 12, 2020, the FDA sent a warning letter to Market America Inc for failure to submit serious adverse event reports about two of its products, as required by federal regulation

"India and China alone represent about a quarter of the worlds adult obese population, and the availability of generic semaglutide will be a big shift in how these countries manage these populations." The market is ripe in countries where semaglutide goes off patent next year, as close to one-third of the worlds adults with obesity live in those countries, says Aurelio Arias, director of thought leadership at Iqvia, a health-information company